18 Results

People

  1. Matasar
    Matasar
  2. Moskowitz
    Moskowitz
  3. Portlock
    Portlock
  4. Gerecitano
    Gerecitano
  5. Noy
    Noy
  6. Zelenetz
    Zelenetz
  7. Palomba
    Palomba
  8. Hamlin
    Hamlin
  9. Straus
    Straus
  10. Moskowitz
    Moskowitz

Groups

  1. Bone Marrow Transplant (18)
  2. Center for Hematologic Malignancies (18)
  3. Department of Medicine (18)
  4. Hematologic Malignancies, Division of (18)
  5. Lymphoma (18)
  6. Survivorship Research (18)
  7. Executive Committee, Center for Hematologic Malignancies (14)
  8. Population Sciences Research Program (13)
  9. Biostatistics Service (11)
  10. Epidemiology and Biostatistics (11)
  1. "Hematologic Malignancies, Division of"
  2. "Bone Marrow Transplant"
  3. "Survivorship Research"
  4. "Department of Medicine"
  5. "Carol Portlock"
Formats
  1. Meeting Abstract (12)
  2. Journal Article (6)
Groups
  1. Bone Marrow Transplant (18)
  2. Center for Hematologic Malignancies (18)
  3. Department of Medicine (18)
  4. Hematologic Malignancies, Division of (18)
  5. Lymphoma (18)
  6. Survivorship Research (18)

More Groups

People
  1. Carol Portlock (18)
  2. Craig Moskowitz (18)
  3. Matthew Matasar (18)
  4. Andrew Zelenetz (17)
  5. Ariela Noy (17)
  6. John Gerecitano (17)

More People

Years
  1. 2021 (1)
  2. 2018 (1)
  3. 2017 (6)
  4. 2016 (3)
  5. 2015 (3)
  6. 2014 (2)

More Years

Publications
  1. Blood (10)
  2. Hematological Oncology (4)
  3. Clinical Lymphoma, Myeloma and Leukemia (1)
  4. Haematologica (1)
  5. Journal of Clinical Oncology (1)
  6. Lancet Oncology (1)
Publishers
  1. American Society of Hematology (10)
  2. Wiley Blackwell (4)
  3. American Society of Clinical Oncology (1)
  4. Elsevier Inc. (1)
  5. Elsevier Science, Inc. (1)
  6. Ferrata Storti Foundation (1)

Results (18)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Noninvasive monitoring of mantle cell lymphoma by immunoglobulin gene next-generation sequencing in a phase 2 study of sequential chemoradioimmunotherapy followed by autologous stem-cell rescue
    Journal Article

    Kumar, A.; Bantilan, K. S.; Jacob, A. P.; Park, A.; Schoninger, S. F.; Sauter, C.; Ulaner, G. A.; Casulo, C.; Faham, M.; Kong, K. A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL
    Journal Article

    Sauter, C. S.; Matasar, M. J.; Schoder, H.; Devlin, S. M.; Drullinsky, P.; Gerecitano, J.; Kumar, A.; Noy, A.; Palomba, M. L.; Portlock, C. S.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Impact of PET staging of follicular lymphoma on treatment outcomes and prognosis
    Meeting Abstract

    Alperovich, A.; Batlevi, C. L.; Intlekofer, A. M.; Moskowitz, C. H.; Horwitz, S. M.; Zelenetz, A. D.; Palomba, M. L.; Moskowitz, A. J.; Gerecitano, J.; Hamlin, P. A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Schòˆder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Cadzin, B. R.; Fox, S. Y.; Gerecitano, J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Defining progression free survival after multiple lines of therapy and impact of dynamic changes in FLIPI for multiply relapsed follicular lymphoma in the rituximab era
    Meeting Abstract

    Batlevi, C.; Alperovich, A.; Ni, A.; Soumerai, J.; Smith, K.; Ying, Z.; Caron, P.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Time from prognosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma
    Meeting Abstract

    Soumerai, J. D.; Ni, A.; Batlevi, C.; Alperovich, A.; Bantilan, K. S.; Palomba, M.; Gerecitano, J. F.; Noy, A.; Hamlin, P.; Moskowitz, C. H.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • A Phase I study of ibrutinib combined with rituximab, ifosfamide, carboplatin, and etoposide in patients with relapsed or primary diffuse large B-cell lymphoma
    Meeting Abstract

    Sauter, C. S.; Matasar, M. J.; Schoder, H.; Drullinsky, P.; Gerecitano, J.; Kumar, A.; Noy, A.; Palomba, M. L.; Portlock, C. S.; Straus, D. J.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Baseline metabolic tumor volume is an independent prognostic factor for relapsed and refractory Hodgkin lymphoma patients receiving PET-adapted salvage therapy with brentuximab vedotin and augmented ICE
    Meeting Abstract

    Moskowitz, A. J.; Schòˆder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Outcomes of follicular lymphoma patients by dynamic FLIPI at diagnosis and initial treatment in the post-rituximab era
    Meeting Abstract

    Batlevi, C.; Alperovich, A.; Smith, K.; Ying, Z.; Soumerai, J. D.; Copeland, A. R.; Joffe, E.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Benchmark of progression free survival for multiple lines of therapy in follicular lymphoma treated in the rituximab era
    Meeting Abstract

    Alperovich, A.; Batlevi, C.; Smith, K.; Ying, Z.; Soumerai, J. D.; Copeland, A. R.; Joffe, E.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; more...
    Blood (2016)

    Fulltext@MSK | Save